Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford R21/Matrix-M™ malaria vaccine receives regulatory clearance for use in Burkina Faso

The University of Oxford-developed, Serum Institute of India PvT Ltd (SIIPL) manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Burkina Faso by the country’s regulatory agency, Agence Nationale de la Regulation Pharmaceutique (ANRP).

African Phase I HIV vaccine trial shows encouraging preliminary results

The multisite Phase I HIV-CORE 006 HIV vaccine clinical trial, run by the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT), has concluded successfully. Preliminary analysis of the immunological trial results demonstrates the induction of high frequencies of broadly specific T cells that recognise functionally conserved regions on HIV-1 and are therefore more protective.

Jenner Institute DPhil Symposium

The Jenner Institute DPhil Symposium on 23 June 2023 brought together over 80 DPhil Students, Research Assistants, Technicians and Apprentices across the Nuffield Department of Medicine to network and share their research and career aspirations. The day was organised entirely by DPhil Students: Adam Khan-Qureshi, Marco Polo Peralta Alvarez, Rebecca Makinson, Samuel Provstgaard-Morys, Meera Madhavan, Christopher De Voss, and Adam Norton-Steele, with the support from Professor Katie Ewer, Assistant Director of Studies at the Jenner Institute.

R21/Matrix-M™ malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana

The University of Oxford-developed and Serum Institute of India PvT Ltd (SIIPL)- manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Ghana by the country’s Food and Drugs Authority.

Mexican Ambassador visits Jenner Institute

The Mexican Ambassador to the United Kingdom, Her Excellency Ms Josefa González-Blanco Ortiz Mena, was given a tour and met with representatives of the Jenner Institute.

Romain Guyon awarded 2022 Michelson Prize

DPhil student at the Jenner Institute, Romain Guyon is among the researchers who received the 2022 Michelson Prizes: Next Generation Grants, announced by Michelson Medical Research Foundation and Human Immunome Project.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two NIHR Biomedical Research Centres (BRC). Professor Helen McShane, Director of the NIHR Oxford BRC and Jenner Investigator said: 'This funding is a recognition of the high calibre work done by our researchers in recent years'.

Blueprint for new adenovirus-based vaccines within 100 days

Jenner researchers have published a pre-print on how new adenovirus-based vaccines could be produced at large-scale within 100 days of identification of a new virus or variant. They also report an improved manufacturing method which could enable production of 1 billion doses per month. The paper is being submitted to BioRxiv and a peer-reviewed journal, and is temporarily available here:

£50m funding for Poonawalla Vaccines Research Building at Oxford University

The Poonawalla Vaccines Research Building is to be established at Oxford University's Old Road Campus following a £50m funding commitment from Serum Life Sciences, a subsidiary of Serum Institute of India. The building will be a new home for the Jenner Institute. The donation will be the University’s largest ever gift for vaccines research.

One week left to apply for Vaccinology Training

In this open call TRANSVAC2 offers free advanced courses on Adjuvants and Vaccine Formulations, Statistics of vaccine evaluation, and Regulatory aspects of vaccine development. Apply until December 15th at

Professor Dame Sarah Gilbert delivers BBC Dimbleby Lecture

Featuring notable speakers from business, science or politics since 1972, Prof. Gilbert delivered the 44th Richard Dimbleby Lecture, held this year at Oxford's Blavatnik School of Government. Dame Sarah Gilbert is the Saïd Professor of Vaccinology, at the Jenner Institute & Nuffield Department of Clinical Medicine. The lecture is available (in the UK) via the BBC iPlayer.

Phase I HIV vaccine trial completes volunteer recruitment in time for World AIDS Day

The Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) is pleased to announce the completion of recruitment of volunteers for the Phase I HIV-CORE 006 HIV vaccine clinical trial at four sites in Kenya, Uganda and Zambia. Enrolment of the final participants took place today at the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya, on World AIDS Day.

Fighting diseases with cross-species vaccination

The 2021 Royal Society Africa Prize Seminar will be given by Professor George Warimwe, Jenner Investigator. More than 70% of these infectious diseases are zoonotic, with some causing illness and death in humans as well as the animal host. Professor Warimwe will discuss his ‘one health' approach to developing a single Rift Valley Fever vaccine suitable for humans and livestock. The lecture will take place online 2 December at 6.30pm GMT.

Jenner Institute named Covid Innovation Heroes

The team at the University of Oxford’s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust’s Covid Innovation Heroes Award­ 2021.

Oxford vaccine reaches two billion dose milestone

University researchers reveal invention of simple manufacturing method which has enabled rapid scale up of vaccine manufacturing in 15 countries around the world, reaching people across seven continents. The approach provides a template for faster and more equitable supply of other vaccines.

$2m fund awarded for Oxford’s single-cell ancestry vaccine research

The University of Oxford is to benefit from $2 million (£1.49 million) in funding from the Chan Zuckerberg Initiative (CZI) to investigate how our ancestry and diversity influence the way that vaccines work in our cells. The Oxford team includes a number of investigators across several departments including the Jenner Institute. Find out more: (

Ebola vaccine to begin human trials

The University of Oxford have begun recruiting for a Phase I trial to test an Ebola vaccine in human volunteers – with the first vaccinations having already taken place.

£200,000 funding boost for Oxford’s Clinical BioManufacturing Facility

The Oxfordshire Local Enterprise Partnership (OxLEP) has secured funding to support the University of Oxford’s Clinical BioManufacturing Facility (CBF) – a UK leader in the production of vaccines for early phase clinical trials, including the Oxford-AstraZeneca vaccine.

Load More